iron metabolism

By Targets:	Ferroportin (2) Apoptosis (6) Atg7 (1) Atg8/LC3 (1) Autophagy (3) Bacterial (2) Bcl-2 Family (1) Biochemical Assay Reagents (1) Caspase (1) CDK (1) Dihydroceramide Desaturase 1 (DES1) (1) Drug Derivative (1) Endogenous Metabolite (3) Ferroptosis (4) Fluorescent Dye (1) G-quadruplex (1) Neuropeptide Y Receptor (2) Reactive Oxygen Species (ROS) (2) Ser/Thr Protease (1) Telomerase (1) TGF-beta/Smad (2) TGF-β Receptor (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (3) Infection (2) Metabolic Disease (10) Neurological Disease (1)
Oligonucleotides:	pH Modifiers (1)

Targets Recommended: Mitochondrial Metabolism Ferroportin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147379

Hepcidin antagonist-1	Ferroportin	Metabolic Disease
Hepcidin antagonist-1 (example 104) is a potent hepcidin (hepcidine) antagonist with an IC₅₀<50 μM. Hepcidin antagonist-1 can be used for researching iron metabolism disorders, such as anemias .

HY-P99359

Elezanumab ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)	TGF-beta/Smad	Metabolic Disease
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC₅₀ around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .

HY-108894

Ferumoxytol	Reactive Oxygen Species (ROS) Ferroptosis	Cancer
Ferumoxytol is an iron oxide nanoparticle. Ferumoxytol has anti-leukemic activity, especially against acute myeloid leukemia (AML) cells with low iron transporter protein (FPN) expression. Ferumoxytol increases intracellular iron content, triggers the Fenton reaction, generates reactive oxygen species (ROS), leads to oxidative stress and ferroptosis. Ferumoxytol can selectively kill leukemic cells with low FPN expression while avoiding toxicity to normal cells. Ferumoxytol can be used to study leukemias with targeted iron metabolism abnormalities .

HY-145965

Ferroportin-IN-1	Ferroportin	Metabolic Disease
Ferroportin-IN-1 is a ferroportin inhibitor extracted from patent WO2020123850A1 compound 23. Ferroportin-IN-1 can be used for the research of diseases caused by a lack of hepcidin or iron metabolism disorders .

HY-P991137

Exerenibart	Ser/Thr Protease	Metabolic Disease
Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .

HY-P3494

Hepcidin-25 (human)	Endogenous Metabolite	Metabolic Disease
Hepcidin-25 (human) is an iron metabolism modulator. Hepcidin-25 (human) shows anti-inflammatory and anti-bacterial activity via modulation of iron-mediated oxidant injury .

HY-135024

Phenylacetyl CoA Phenylacetyl Coenzyme A	Endogenous Metabolite	Metabolic Disease
Phenylacetyl CoA is an acceptor oxidoreductase. Phenylacetyl CoA is a membrane-bound molybdenum–iron–sulfur enzyme involved in anaerobic metabolism of phenylalanine in the denitrifying bacterium Thauera aromatica .

HY-135024A

Phenylacetyl CoA lithium Phenylacetyl coenzyme A lithium; S-(Benzeneacetate)-CoA lithium; S-(Benzeneacetate)-coenzyme A lithium	Endogenous Metabolite	Metabolic Disease
Phenylacetyl CoA lithium (Phenylacetyl Coenzyme A lithium) is an acceptor oxidoreductase. Phenylacetyl CoA is a membrane-bound molybdenum–iron–sulfur enzyme involved in anaerobic metabolism of phenylalanine in the denitrifying bacterium Thauera aromatica .

HY-157433

Mab-SaS-IN-1	Bacterial	Infection
Mab-SaS-IN-1 (compoud 1H) is Mab-SaS inhibitor with the IC₅₀ of 2 μM. Mab-SaS-IN-1 can be used for study of antibiosis by blocking iron uptake and metabolism .

HY-148205A

Trypanothione TFA	Drug Derivative	Others
Trypanothione TFA is a bis-glutathionyl derivative, found in trypanosomatids. Trypanothione TFA itself or assisted by different enzymatic systems is involved in anti-oxidant defense, cell proliferation, removal of toxic compounds and metabolites and iron-sulfur metabolism .

HY-149353

Antibacterial agent 145	Bacterial	Infection
Antibacterial agent 145 (compound 1b) is an antibacterial agent depending on bacterial iron uptake pathway. Antibacterial agent 145 disrupts cytoplasmic membrane integrity and inhibits cell metabolism but exhibits low cytotoxic effects to normal cells .

HY-119325

Lanperisone NK433 free base	Apoptosis	Cancer
Lanperisone is a novel oral muscle relaxant with anticancer activity. Lanperisone produces non-apoptotic cell death by inhibiting monosynaptic and polysynaptic reflex potentials. Lanperisone is also believed to play an important role in the dysregulation of iron metabolism and antioxidant systems to modulate processes associated with ischemic stroke .

HY-119325A

Lanperisone hydrochloride NK433	Apoptosis	Cancer
Lanperisone hydrochloride is a novel oral muscle relaxant with anticancer activity. Lanperisone hydrochloride produces non-apoptotic cell death by inhibiting monosynaptic and polysynaptic reflex potentials. Lanperisone hydrochloride is also believed to play an important role in the dysregulation of iron metabolism and antioxidant systems to modulate processes associated with ischemic stroke .

HY-D1533

RhoNox-1 Maximum Cited Publications 25 Publications Verification	Fluorescent Dye	Others
RhoNox-1 is a fluorescent probe for the specific detection of divalent iron ions, and when RhoNox-1 reacts with Fe ²⁺. RhoNox-1 can generate an irreversible orange (red) fluorescent product (Ex/Em：540/575 nm) . FeRhoNox-1 can enter the cell well, suitable for the detection of Fe ²⁺ in living cells, and tends to be localized in the Golgi apparatus .

HY-179052

Apoptosis inducer 50	Apoptosis Autophagy Bcl-2 Family Caspase Atg8/LC3 Atg7 CDK Reactive Oxygen Species (ROS)	Cancer
Apoptosis inducer 50 (Compound 5e) is an apoptosis inducer as well as an autophagy inducer agent. Apoptosis inducer 50 exhibits potent and selective anti-cancer activity against triple-negative breast cancer cells and metastatic colon cancer cells. Apoptosis inducer 50 upregulates the expression of pro-apoptotic proteins (Bax, Bim, cleaved Caspase-9) and downregulates the expression of the anti-apoptotic protein (BCL-XL). Apoptosis inducer 50 upregulates key autophagy markers such as Beclin-1 and ATG5, and enhances the conversion of LC3-I to LC3-II., Apoptosis inducer 50 arrests cancer cells in the G1/S phase by upregulating the expression of p21 and p27 while downregulating Cyclin D1. Apoptosis inducer 50 increases the level of ROS .

HY-163472

PR280	Dihydroceramide Desaturase 1 (DES1)	Metabolic Disease Cancer
PR280 is a potent inhibitor of dihydroceramide desaturase 1 (Des1) (IC₅₀=700 nM). PR280 forms hydrogen bonds with the amino acid residues of Des1, and its cyclopropenone group may form a coordination with the iron center, thus stabilizing the binding to the active site of Des1 and inhibiting the sphingosine lipid synthesis pathway of dihydroceramide (dhCer) to form ceramide. PR280 can be used in the study of diseases related to sphingosine lipid metabolism, such as cancer and metabolic diseases .

HY-162688

Anticancer agent 239	Telomerase G-quadruplex Apoptosis Ferroptosis	Others
Anticancer agent 239 (Compound 5) is a ligand of hTERT promoter G-quadruplex DNA structures (hTERT G4) (K_d = 1.1 μM), and downregulates hTERT expression. Anticancer agent 239 decreases telomerase activity, shortens telomere length, and induces DNA damage, acute cellular senescence, and apoptosis. Anticancer agent 239 causes mitochondrial dysfunction, disrupts iron metabolism and activates ferroptosis in cancer cells. Anticancer agent 239 inhibits tumor growth in MDA-MB-231 xenograft mouse model .

HY-W088066

Trisodium phosphate dodecahydrate	Biochemical Assay Reagents	Others
Trisodium phosphate dodecahydrate is a corrosion inhibitor for iron in 0.1 M NaClO4, in both aerated and deaerated solutions. Trisodium phosphate dodecahydrate can be used as an excipient, such as pH regulator, buffer. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .

HY-P1723

Spexin 2 Publications Verification Neuropeptide Q	Neuropeptide Y Receptor Apoptosis Ferroptosis Autophagy	Cardiovascular Disease Neurological Disease
Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .

HY-P1723A

Spexin TFA Neuropeptide Q TFA	Neuropeptide Y Receptor Apoptosis Ferroptosis Autophagy	Cardiovascular Disease Metabolic Disease
Spexin (Neuropeptide Q) TFA is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin TFA can function through both central and peripheral actions. Spexin TFA upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin TFA improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin TFA can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .

HY-P99590A

Sotatercept (mIgG2a) RAP-011	TGF-β Receptor TGF-beta/Smad	Cardiovascular Disease Metabolic Disease
Sotatercept (mIgG2a) (RAP-011), the murine homolog of Sotatercept (ACE-011) (HY-P99590), is a soluble activin receptor type IIA (ActRIIA) ligand trap. Sotatercept (mIgG2a) inhibits the binding of activin A and other members of the TGF-β superfamily (such as Activin A/B, GDF11 and BMP9/10) to their receptors by combining and neutralizing them, thereby regulating cell proliferation and differentiation. Sotatercept (mIgG2a) mainly inhibits the SMAD2/3 signaling pathway, and can be used in various diseases such as chronic kidney disease. Sotatercept (mIgG2a) reduces the expression of erythropoietic hepcidin (ERFE), regulates iron metabolism, and promotes red blood cell production. Sotatercept (mIgG2a) has a dual effect of promoting bone formation (anabolic) and inhibiting bone resorption (catabolic) .

Cat. No.	Product Name

HY-L133

Cuproptosis Compound Library	318 compounds
Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis". The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis. Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism. Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis. MCE supplies a unique collection of 318 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.

Cuproptosis Compound Library

318 compounds

Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis".

The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis.

Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism.

Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis.

MCE supplies a unique collection of 318 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.

Cat. No.	Product Name	Type